Boehringer

Adimab Provides Year-End Update on 2018 Partnership Activities

Retrieved on: 
Tuesday, January 8, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Research, Science, Biotechnology, Nature, Health, Boehringer Ingelheim, Sanofi, Biopharmaceutical, Boehringer

In 2018, Adimab and its partners added 56 new therapeutic programs.

Key Points: 
  • In 2018, Adimab and its partners added 56 new therapeutic programs.
  • New alliances for 2018 include collaborations with Biotheus, Boehringer Ingelheim, Cullinan Oncology, Cygnal Therapeutics, Pliant Therapeutics, REGiMMUNE, and Werewolf Therapeutics, among others.
  • In addition, Adimab expanded its collaborations with Boehringer Ingelheim, Innovent Biologics, Mapp Biopharmaceutical, Sanofi, Surface Oncology, and Takeda.
  • In addition to being the leader for antibody discovery, Adimab has become the go-to provider for bispecifics and protein engineering.

Angels Initiative Wins the Prestigious 2018 EFPIA Health Collaboration Award for Improving Stroke Care

Retrieved on: 
Thursday, December 20, 2018
Health, European Federation of Pharmaceutical Industries and Associations, Boehringer Ingelheim, Stroke Alliance for Europe, Europe, Boehringer, Stroke, Pharmaceutical industry, World Stroke Day

OXFORD, England, Dec. 20, 2018 /PRNewswire/ --The Angels Initiative, a unique healthcare initiative launched by Boehringer Ingelheim in partnership with the European Stroke Organisation (ESO), the World Stroke Organisation (WSO) and the Stroke Alliance for Europe (SAFE), is this year's winner of the prestigious European Federation of Pharmaceutical Industries and Associations (EFPIA) "Health Collaboration" award in the category Service Delivery.

Key Points: 
  • OXFORD, England, Dec. 20, 2018 /PRNewswire/ --The Angels Initiative, a unique healthcare initiative launched by Boehringer Ingelheim in partnership with the European Stroke Organisation (ESO), the World Stroke Organisation (WSO) and the Stroke Alliance for Europe (SAFE), is this year's winner of the prestigious European Federation of Pharmaceutical Industries and Associations (EFPIA) "Health Collaboration" award in the category Service Delivery.
  • The Angels Initiative is aiming to increase the number of stroke ready hospitals and to optimise the quality of treatment in stroke centres across Europe and beyond.
  • This award showcases our strong commitment to improving stroke treatment through collaboration.
  • We are looking forward to carry on supporting fast and consistent stroke imaging to hospitals who are part of the Angels Initiative."

Bernardo Romero Joins Grey New York As Executive Creative Director

Retrieved on: 
Wednesday, December 19, 2018
Lomb, Economy of the United States, FCB, Boehringer Ingelheim, Walgreens, Fitbit, Bausch, Boehringer, Industrial organization, Health care

NEW YORK, Dec. 19, 2018 /PRNewswire/ --John Patroulis, Worldwide Chief Creative Officer of Grey, today announced that Bernardo Romero has joined Grey New York as Executive Creative Director for health-related business.

Key Points: 
  • NEW YORK, Dec. 19, 2018 /PRNewswire/ --John Patroulis, Worldwide Chief Creative Officer of Grey, today announced that Bernardo Romero has joined Grey New York as Executive Creative Director for health-related business.
  • Bernardo Romero joins from Area 23, an agency of the FCB Health Network, which he joined in 2016, rising to Executive Creative Director.
  • His arrival underscores our commitment to invest 75 cents of every Grey dollar in senior creative talent by 2019."
  • Grey New York serves a blue-chip roster of health-related clients including Walgreens, Lilly, GSK, Pfizer, Bausch & Lomb, Boehringer-Ingelheim, Fitbit and UPMC.

AGC Enters Agreement to Acquire Synthetic Pharmaceutical Active Ingredient-manufacturing Plant in Spain

Retrieved on: 
Tuesday, December 4, 2018
Health, Pharmaceutical industry, Pharmacology, Pharmacy, Boehringer Ingelheim, Boehringer, Medicinal chemistry

MPC is a subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical active ingredients (*1) for the group.

Key Points: 
  • MPC is a subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical active ingredients (*1) for the group.
  • By acquiring MPC, AGC will have its first FDA-registered site in Europe in the synthetic pharmaceutical CDMO (*2) business.
  • The AGC Group's "AGC plus" management policy identifies life sciences as one of its strategic businesses.
  • (*1) Synthetic pharmaceutical intermediates and active ingredients:Intermediates and active ingredients for pharmaceutical products that areproduced by chemical synthesis.

AGC Enters Agreement to Acquire Synthetic Pharmaceutical Active Ingredient-manufacturing Plant in Spain

Retrieved on: 
Tuesday, December 4, 2018
Health, Pharmaceutical industry, Pharmacology, Pharmacy, Boehringer Ingelheim, Boehringer, Medicinal chemistry

MPC is a subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical active ingredients (*1) for the group.

Key Points: 
  • MPC is a subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical active ingredients (*1) for the group.
  • By acquiring MPC, AGC will have its first FDA-registered site in Europe in the synthetic pharmaceutical CDMO (*2) business.
  • The AGC Group's "AGC plus" management policy identifies life sciences as one of its strategic businesses.
  • (*1) Synthetic pharmaceutical intermediates and active ingredients:Intermediates and active ingredients for pharmaceutical products that areproduced by chemical synthesis.

Global Personalized Medicine Market 2017-2018 & 2024: Market is Projected to Reach US$194.4 Billion by 2024 from an Estimated US$92.4 Billion in 2017

Retrieved on: 
Monday, October 15, 2018
Health, Medicine, Myriad Genetics, Daiichi Sankyo, Boehringer Ingelheim, HER2/neu, Pharmaceutical industry in China, Boehringer, Steatohepatitis, Pharmaceutical industry in India, Pharmaceutical industry

Abbott Develops Deep Brain Stimulation System, Life-Changing Treatment

Key Points: 
  • Abbott Develops Deep Brain Stimulation System, Life-Changing Treatment
    Myriad Genetics Inc to Acquire Counsyl, Inc
    Abbott Laboratories Inc and SurModics, Inc Enter into Agreement on Next-Generation Drug-Coated Balloon
    Boehringer Ingelheim GmbH and Dicerna Pharmaceuticals, Inc Agree on Nonalcoholic Steatohepatitis (NASH) Treatment Development
    Bristol-Myers Squibb and Daiichi Sankyo Co., Ltd Enter into Clinical Collaboration in HER2-Expressing Breast and Bladder Cancers
    Myriad Genetics Inc and BeiGene, Ltd Collaborate on Companion Diagnostics Development for Personalized Medicine Drive

Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial

Retrieved on: 
Thursday, October 4, 2018
Health, States of Germany, Anti-diabetic drugs, Chemistry, Glucosides, SGLT2 inhibitors, Boehringer Ingelheim, Empagliflozin, Linagliptin, Gliflozin, Eli Lilly and Company, Boehringer

CARMELINA was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance.

Key Points: 
  • CARMELINA was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance.
  • In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME with the SGLT2 inhibitor empagliflozin.
  • CAROLINA, will be the first DPP-4 inhibitor cardiovascular outcome trial to compare commonly used second line treatments Tradjenta and the sulfonylurea glimepiride.
  • Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, Conn., is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Stephen Davies Appointed Vice President, Eisai Strategic Information Systems at Eisai Inc.

Retrieved on: 
Monday, August 27, 2018
Health, States of Germany, Eisai, Rhineland-Palatinate, Boehringer Ingelheim, Pharmaceutical industry in China, ImClone Systems, Pharmaceutical industry, Boehringer, Ingelheim am Rhein

WOODCLIFF LAKE, N.J., Aug. 27, 2018 /PRNewswire/ --Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Stephen Davies as Vice President, Eisai Strategic Information Systems.

Key Points: 
  • WOODCLIFF LAKE, N.J., Aug. 27, 2018 /PRNewswire/ --Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Stephen Davies as Vice President, Eisai Strategic Information Systems.
  • Mr. Davies will be responsible for leading the information technology (IT) function for Eisai's Americas region, as well as the company's global clinical and global regulatory solutions.
  • Mr. Davies joins Eisai from Gartner Inc., where he spent the past four years as Research Director, Life Sciences.
  • Prior to Gartner, Mr. Davies served in executive IT roles at Savient Pharmaceuticals, Inc., Imclone Systems, and Boehringer Ingelheim.

Annual National Veterinary Scholars Symposium Showcases Young Talent And Value Of Hands-On Research Opportunities For Students

Retrieved on: 
Monday, August 6, 2018
Veterinary education, Boehringer Ingelheim, Veterinary physician, Boehringer, Health, Economy of Germany

The National Veterinary Scholars Symposium, the premier annual scientific colloquium which showcases research accomplishments by veterinary students completing summer research internships, provides an opportunity for students participating in the Boehringer Ingelheim Veterinary Scholars program to present their research findings by oral and/or poster presentation.

Key Points: 
  • The National Veterinary Scholars Symposium, the premier annual scientific colloquium which showcases research accomplishments by veterinary students completing summer research internships, provides an opportunity for students participating in the Boehringer Ingelheim Veterinary Scholars program to present their research findings by oral and/or poster presentation.
  • The mission of theBoehringer Ingelheim Veterinary Scholars Program is to provide an opportunity for veterinary schools to introduce first and second-year veterinary medical students to biomedical research.
  • At each of the more than three dozen participating institutions, Boehringer Ingelheim Veterinary Scholars are assigned to a mentor and laboratory.
  • Scheduled activities supplement the research work, to provide opportunities for the students to learn about the broad aspects of research.

ZS and Rock Health Announce Partnership in Digital Health

Retrieved on: 
Monday, June 18, 2018
Business, Economy, Management, Boehringer Ingelheim, Rock Health, Boehringer, Accenture, ZS, Ingelheim am Rhein, Novo Nordisk

EVANSTON, Ill., June 18, 2018 /PRNewswire/ --Global sales and marketing firm ZS is excited to announce a new partnership with Rock Health, a full-service venture fund that supports startups and entrepreneurs working in digital health.

Key Points: 
  • EVANSTON, Ill., June 18, 2018 /PRNewswire/ --Global sales and marketing firm ZS is excited to announce a new partnership with Rock Health, a full-service venture fund that supports startups and entrepreneurs working in digital health.
  • Digital health investments and innovations continue to grow at an ever-increasing pace, making digital health among the key disruptive forces that will shape the future of healthcare.
  • Combined with Rock Health's deep expertise in innovation and digital health, our partnership will help both digital health innovators and pharma and medtech companies be more successful with their digital health efforts."
  • Rock Health partners include AbbVie, Accenture, Blue Shield of California, Boehringer Ingelheim, Boston Children's Hospital, CVS Health, DaVita, Novo Nordisk, Sutter Health, Takeda and ZS Associates.